CDKN2A and glioblastoma: They reported that MTAP can identify CDKN2A status with 88% sensitivity and 98% specificity in astrocytoma Isocitrate dehydrogenase (IDH) mutant tumors, and 89% sensitivity and 100% specificity in glioblastoma, IDH-wildtype.